FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

ANDA Amendments for Tentatively Approvals

[ Price : $8.95]

FDA issues a guidance entitled ANDA Submissions Amendments and Requests for Final Approval to Tentatively Approved ANDAs.

Panel to Review Biogen Alzheimers BLA

[ Price : $8.95]

Federal Register notice: FDA announces an 11/6 Advisory Committee meeting to review a Biogen BLA for aducanumab solution for treat...

ANDA Guide on Failing to Respond to CRLs

[ Price : $8.95]

FDA posts a draft guidance entitled Failure to Respond to an ANDA Complete Response Letter Within 1 the Regulatory Timeframe.

Federal Register Corrected on Kadom Pharma ANDAs

[ Price : $8.95]

Federal Register notice: FDA corrects a notice that appeared in the 7/21 Federal Register announcing the withdrawal of approval fo...

Final Rule on Drug Importation from Canada

[ Price : $8.95]

Federal Register notice: FDA issues a final rule to allow importation of certain prescription drugs from Canada.

Shionogi Expanded Use for Fetroja

[ Price : $8.95]

FDA approves a Shionogi & Co. supplemental NDA for Fetroja (cefiderocol) for treating patients 18 years of age or older with hospi...

Vaccines Panel Chair Recuses Herself Over Conflict

[ Price : $8.95]

FDA vaccines advisory committee chair Hana El Sahly recuses herself from reviewing any upcoming pandemic vaccines because of her r...

First Serology Covid Point-of-Care Test Authorized

[ Price : $8.95]

FDA issues Assure Tech an emergency use authorization for the first serology (antibody) point-of-care test for Covid-19.

BMS Reports Opdivo Positive Data in Urothelial Carcinoma

[ Price : $8.95]

Bristol Myers Squibb says an Opdivo (nivolumab) Phase 3 trial in patients post-surgery with high-risk, muscle-invasive urothelial ...

3 Guidances for Conformity Assessment Pilot Program

[ Price : $8.95]

Federal Register notice: FDA makes available three final guidance documents for its Accreditation Scheme for Conformity Assessment...